{"doi":"10.1002/ajim.23278","title":"Cancer survival among World Trade Center rescue and recovery workers: A collaborative cohort study","abstract":"BACKGROUND: World Trade Center (WTC)-exposed responders may be eligible to receive no-cost medical monitoring and treatment for certified conditions, including cancer. The survival of responders with cancer has not previously been investigated. METHODS: This study compared the estimated relative survival of WTC-exposed responders who developed cancer while enrolled in two WTC medical monitoring and treatment programs in New York City (WTC-MMTP responders) and WTC-exposed responders not enrolled (WTC-non-MMTP responders) to non-responders from New York State (NYS-non-responders), all restricted to the 11-southernmost NYS counties, where most responders resided. Parametric survival models estimated cancer-specific and all-cause mortality. Follow-up ended at death or on December 31, 2016. RESULTS: From January 1, 2005 to December 31, 2016, there were 2,037 cancer cases and 303 deaths (248 cancer-related deaths) among WTC-MMTP responders, 564 cancer cases, and 143 deaths (106 cancer-related deaths) among WTC-non-MMTP responders, and 574,075 cancer cases and 224,040 deaths (158,645 cancer-related deaths) among the NYS-non-responder population. Comparing WTC-MMTP responders with NYS-non-responders, the cancer-specific mortality hazard ratio (HR) was 0.72 (95% confidence interval [CI] = 0.64-0.82), and all-cause mortality HR was 0.64 (95% CI = 0.58-0.72). The cancer-specific HR was 0.94 (95% CI = 0.78-1.14), and all-cause mortality HR was 0.93 (95% CI = 0.79-1.10) comparing WTC-non-MMTP responders to the NYS-non-responder population. CONCLUSIONS: WTC-MMTP responders had lower mortality compared with NYS-non-responders, after controlling for demographic factors and temporal trends. There may be survival benefits from no-out-of-pocket-cost medical care which could have important implications for healthcare policy, however, other occupational and socioeconomic factors could have contributed to some of the observed survival advantage.","journal":"American Journal of Industrial Medicine","year":2021,"id":187409,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.919,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":690451,"name":"Rachel Zeig‐Owens","orcid":"0000-0002-8679-2306","position":1,"is_corresponding":false},{"id":691986,"name":"Dana Kristjansson","orcid":"0000-0003-0687-2910","position":2,"is_corresponding":false},{"id":691976,"name":"Jiehui Li","orcid":"0000-0002-7812-8878","position":3,"is_corresponding":false},{"id":691981,"name":"Robert M. Brackbill","orcid":"0000-0003-0518-0330","position":4,"is_corresponding":false},{"id":691982,"name":"Mark R. Farfel","orcid":"0000-0002-9952-9937","position":5,"is_corresponding":false},{"id":691980,"name":"James E. Cone","orcid":"0000-0003-2145-1348","position":6,"is_corresponding":false},{"id":536216,"name":"Amy R. Kahn","orcid":"0000-0002-1025-6312","position":7,"is_corresponding":false},{"id":691978,"name":"Baozhen Qiao","orcid":"0000-0002-8407-7835","position":8,"is_corresponding":false},{"id":390441,"name":"Maria J. Schymura","orcid":"0000-0003-0587-8667","position":9,"is_corresponding":false},{"id":690449,"name":"Mayris P. Webber","orcid":"0000-0002-8322-4573","position":10,"is_corresponding":false},{"id":691984,"name":"Christopher R. Dasaro","orcid":"0000-0002-9924-195X","position":11,"is_corresponding":false},{"id":275023,"name":"Roberto G. Lucchini","orcid":"0000-0002-9723-0237","position":12,"is_corresponding":false},{"id":691985,"name":"Andrew C. Todd","orcid":"0000-0001-7864-009X","position":13,"is_corresponding":false},{"id":690456,"name":"David J. Prezant","orcid":"0000-0001-9562-0330","position":14,"is_corresponding":false},{"id":690454,"name":"Charles B. Hall","orcid":"0000-0001-9982-8120","position":15,"is_corresponding":false},{"id":265963,"name":"Paolo Boffetta","orcid":"0000-0002-3811-2791","position":16,"is_corresponding":false},{"id":690455,"name":"David G. Goldfarb","orcid":"0000-0003-2682-7543","position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-18T23:48:55.420619Z","pmid":"34288025","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}